HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Clinical trial NCT05338970 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05338970
Sponsor: Daiichi Sankyo
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Nonsquamous Non-small Cell Lung Cancer EGFR L858R EGFR Exon 19 Deletion

Start date: 2022-07-08
Primary completion: 2024-05-31
Enrollment: 586

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.